For adults and children with hemophilia B
LONG-LASTING BLEED PROTECTIONFOR THE WORKHORSE WITHIN
ONLY IDELVION DELIVERS
Zero median annualized spontaneous bleeding rate in adults when dosed at 7 or 14 days in phase III pivotal trials
EXPLORE IDELVIONEFFICACY
*The median AsBR for patients who started and stayed on 7- or 14-day prophylaxis was 0. For patients who switched to prophylaxis from on-demand, the median AsBR was 0.7.
†In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month while not requiring dose adjustments or experiencing spontaneous bleeding.
‡The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg.
Join us for a live webcast event!
Join us for an engaging discussion with a leading hematologist about the treatment of hemophilia B, an actual patient case study, and a clinical overview of IDELVION.
12 PM EST
With Dr. Shveta Gupta
2 PM EST
With Dr. Mark Reding
Print the enrollment form
So your patients can see if it’s right for them
Recommended for mobile devices
Resources for your patients
CSL Behring is committed to providing treatments and support services that make a meaningful difference in the lives of people with bleeding disorders.
Resources are available to help your patients get the treatment they need for hemophilia B, including:
- A free trial of IDELVION
- Co-pay assistance for eligible patients for up to $12,000 of annual out-of-pocket expenses
- Lapse-in-coverage support with the CSL Behring AssuranceSM program
- Reimbursement and access support
References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735.